DDFU/DRUGU (Derwent Drug File)
DDFU
DRUGU

Derwent Drug File Standard
Derwent Drug File for Subscribers(Former closed files DDFB/DRUGB are integrated)

Subject
Coverage

All aspects of drugs:• Analysis• Biochemistry• Galenics• Metabolism• Pharmacokinetics• Pharmacology• Synthesis• Therapeutics and Adverse Effects• Toxicology

File Type

Bibliographic

Features

Thesaurus

Controlled Term (/CT)

Alerts (SDI)

Weekly or monthly (weekly is the default)

CAS Registry
Number® IdentifiersKeep & Share



SLART



RecordContent• Bibliographic information, Derwent's abstract (and extension abstract in file DRUGU
only), and controlled term indexing.

File SizeMore than 2.77 million records (09/2023)

Coverage

1964–present

Updates

WeeklyLanguage

EnglishSeptember 2023

2
DDFU/DRUGU

Database
Producer

Clarivate
Friars House, 160 Black Friars Rd.
London SE1 8EZ
United Kingdom
Copyright Holder: Clarivate

Sources• 1,100 Medical and scientific journals and conference proceedings

User Aids• Derwent Drug File Thesaurus *• Online Helps (HELP DIRECTORY lists all help messages available)• STNGUIDE* available from the producer and online

Cluster• ALLBIB• AUTHORS• BIOSCIENCE• CORPSOURCE• FORMULATIONS• MEDICINE• PHARMACOLOGY• TOXICOLOGYSTN Database Cluster information:
http://www.stn-international.com/en/customersupport/customersupport#cluster+%7C+subjects+%7C+features

September 2023

3
DDFU/DRUGU

Search and Display Field Codes
Fields that allow left truncation are indicated by an asterisk (*).

Search Field Name

SearchCode

Display
Codes

Search Examples

Basic Index* (contains single
words from title (TI), controlled
term (CT), abstract (AB), andextension abstract (ABEX))

None
or
/BI

S ANTI-TUMOR(P)TOXIC EFFECT#S CYCLOPHOSPHAMIDE

TI, AB,ABEX (1), CT

Abstract*
Abstract, Extension* (1)Accession Number
AuthorAvailability of Document (2)(Reprint Address)
Classification Code (2)(code and text)
Controlled Term (3,4)(limited by roles)

/AB
/ABEX
/AN
/AU
/AV

S (DNA AND PROTEIN)/AB
S ?PHENYLETHER?/ABEX
S 1994-00609/AN
S TEELMANN K/AUS HARVARD UNIV/AVAB
ABEX (1)
AN
AU
AV

/CC

CC

Corporate Source (2)Derwent Drug Registry Name
Document Type(code and text)
Entry Date (6)Field Availability
International Standard(Document) Number (CODEN
and ISSN)
Index Term (7)Journal Title
Language(ISO code and text)
Location (2)

/CS
/DDRN
/DT
(or /TC)
/ED
/FA
/ISN

S 73/CCS TRIAL PREPARATIONS/CC
S MARROW-DISEASE/CT
S MARROW-DISEASE *AE/CT(P)CYCLOPHOSPHAMIDE *AE/CTS NIPPON ROCHE/CSS FALIMINT/DDRNS JOURNAL/DT
S J/DT
S L8 AND ED>20220901
S L7 AND AB/FA
S 0020-7136/ISN
S IJCNAW/ISN

IT
SO
LA

Multipunch Code (1,8)
Publication Year (6)Source (contains journal title,
ISSN, CODEN, collation, andreprint address)
Subject Heading(code and text)
Title*
Update Date (6)

/MPC
/PY
/SO

S THIOPHENE/ITS INT J CANCE?/JTS L7 AND DE/LAS GERMAN/LA
S (BASLE OR BASEL)/LO
S KANAGAWA JAP?/LOS MCI-154 *PI/MPC
S 1990-1992/PY
S INT J CANCE?/SOS IJCNAW/SO
S 0020-7136/SO
S S/SH AND L10
S ADVERSE EFFECTS/SHS COVID 19 PANDEMIC/TI
S L8 AND UP>20221001

/CT

/IT
/JT
/LA
/LO

/SH
/TI
/UP

CT

CS
CT
DT
ED
FA
SO

LO
MPC
SO
SO

SH
TI
UP

(1) This field is available for display in the Derwent Subscriber file DRUGU only
(2) Search with implied (S) proximity is available in this field.
(3) Field available for data since 1983, a thesaurus is available in this field.
(4) There are 9 roles available in field /CT to limit a search to a particular aspect of a drug or a disease: AE Adverse Effects, DI Drug
Interactions, DM Drug Metabolism, FT Further Term (assigned when no other role assigned), OC Other Context, PH Pharmacology,
RC Reference Compound, RN Registry Name, TR Treatment. Controlled terms concerning the same drug in a record are linked by(P) proximity.
(6) Numeric search field that may be searched using numeric operators or ranges.
(7) Field available for data until 1983.
(8) Search with implied (P) proximity is available in this field. Multipunch codes concerning the same drug in a record are linked by (L)proximity.

September 2023

4
DDFU/DRUGU

Derwent Drug File Thesaurus
The Derwent Drug File Thesaurus is available online in field /CT (Controlled Term). All relationships codes
can be used with both the EXPAND and SEARCH command.

Field

Relationship
Code

/CT

ALL
AUTO (1)
BT
HIE
NT
PFT
RT
UF
USE

Content
All Associated Terms (BT, SELF, USE, UF, SEE,
NEW, OLD, TN, EC, CN, RT, NT, NOTE)
Automatic Relationship (SELF, USE, UF, SEE,
NEW, OLD, TN, EC, CN, NT)
Broader Terms (also BT1, BT2 etc. possible)
Hierarchy Terms (BT, SELF, NT)
Narrower Terms (also NT1, NT2 etc. possible)
All Preferred and Forbidden Terms
Related Terms (see also)
Used for (Preferred and Forbidden Terms)
Use Forbidden and Preferred Terms

SearchExamplesE LOBAPLATIN+ALL/CT
E CLOPIDOGREL+AUTO/CT
E LEGIONNAIRE-DISEASE+BT/CT
E PNEUMONIA+HIE/CT
E CLOPIDOL+PFT/CTE XYLAMIDE+RT/CT
E FORMALDEHYDE+UF/CT
E FORMALIN+USE/CT(1) Automatic Relationship is SET OFF. In case of SET REL ON, the result of EXPAND or SEARCH without any relationship code is thesame as described for AUTO.

September 2023

5
DDFU/DRUGUDISPLAY and PRINT Formats
Any combination of formats may be used to display or print answers. Multiple codes must be separated by
spaces or commas, e.g., D L1 1-5 TI AU. The fields are displayed or printed in the order requested.
Hit-term highlighting is available for all fields. Highlighting must be ON during SEARCH to use the HIT, KWIC,
and OCC formats.
FormatContent

ExamplesAB
ABEX (1)
AN
AU
AV
CC
CS
CT
DDRN (2)DT (TC)ED (2)FA
ISN (2)IT
JT (2)LA
LO
MPC (1)
PY (2)SH
SO
TI
UP (2)

Abstract
Abstract Extension
Accession Number
AuthorAvailability of Document (Reprint Address)
Classification CodeCorporate Source
Controlled Term)
Derwent Drug Registry Name
Document Type
Entry Date
Field Availability
International Standard (Document) Number
Index Term
Journal Title
Language
Location
Multipunch CodePublication Year
Subject Heading
SourceTitle
Update Date

D TI AB 1-4
D ABEXDIS AND AU TI 1-10
D TI AV 1-5
D CC
D TI CS AB
D CT
D DDRND DT
D AN EDD AN FA
D JT ISN
D IT
D JT
D LA
D CS LO
D MPC
D PY
D SH
D TI AU SO 1-10
D TI 5
D UP

ABS
ALL
IALL
BIB
IBIB
IND
MAX

D ABS
D ALL
D IALLD BIB
D IBIBD IND
D MAX

SCAN (3)
TRIAL (TRI, SAM)

AN, AB, ABEX (1)AN, TI, AU, CS, LO, SO, AV, LA, DT, AB, SH, CC, CT, IT, FA
ALL, Indented with text labels
AN, TI, AU, CS, LO, SO, AV, LA, DT, FA
BIB, indented with text labels
AN, SH, CC, CT, MPC (1)AN, TI, AU, CS, LO, SO, AV, LA, DT, AB, ABEX (1), SH, CC, CT, IT,
MPC (1)
TI, CC, CT
AN, TI, CC, CT, IT

HIT
KWIC
OCC

Hit term(s) and field(s)Up to 50 words before and after hit term(s) (KeyWord-In-Context)
Number of occurrences of hit term(s) and field(s) in which they occur

D HIT
D KWIC
D OCC

D TRIAL(1) This field is available in the Derwent Subscriber file DRUGU only.
(2) Custom display only.
(3) SCAN must be specified on the command line, i.e., D SCAN or DISPLAY SCAN.

September 2023

6
DDFU/DRUGUSELECT, ANALYZE, and SORT Fields
The SELECT command is used to create E-numbers containing terms taken from the specified field in ananswer set.
The ANALYZE command is used to create an L-number containing terms taken from the specified field in ananswer set.
The SORT command is used to rearrange the search results in either alphabetic or numeric order of thespecified field(s).
Field Name
Abstract
Abstract Extension
Accession Number
AuthorAvailability of Document (Reprint Address)
Classification Code
CODEN
Controlled Term
Corporate Source
Derwent Drug Registry Name
Document Type
Entry Date
Field Availability
International Standard (Document) Number
International Standard Serial Number
Index Term
Journal Title
Language
Location
Multipunch CodeOccurrence Count of Hit Terms
Publication Year
SourceSubject Heading
Title
Update Date

Field CodeAB
ABEX (2)
AN
AU
AV
CC
CODEN
CT
CS
DDRN
DT (TC)
ED
FA
ISN
ISSN
IT
JT
LA
LO
MPC (2)
OCC
PY
SO
SH
TI
UP

ANALYZE/
SELECT (1)

SORT

Y
Y
Y
Y
Y
Y
N
Y
Y
Y (3)
Y
Y
Y (3)
Y (4)
N
Y (6)
Y
Y
Y
Y
N
Y
Y (5)
Y
Y (default)
Y

N
N
N
Y
Y
Y
Y
N
Y
N
Y
Y
Y
Y
Y
Y
Y
Y
Y
N
Y
Y
N
Y
Y
Y

(1) HIT may be used to restrict terms extracted to terms that match the search expression used to create the answer set,e.g., SEL HIT TI.
(2) This field is available in the Derwent Subscriber file DRUGU only.
(3) SELECT HIT and ANALYZE HIT may not be used with this field.
(4) Selects or analyzes CODEN and ISSN with /ISN appended to the terms created by SELECT.
(5) Selects or analyzes CODEN and ISSN with /SO appended to the terms created by SELECT.
(6) Field available for data until 1983

September 2023

7
DDFU/DRUGU

Sample Records
DISPLAY IALLACCESSION NUMBER:
TITLE:AUTHOR(S):CORPORATE SOURCE:
LOCATION:
SOURCE:AVAILABILITY:LANGUAGE:
DOCUMENT TYPE:
ABSTRACT:SUBJECT HEADING:
CLASSIFICATION CODE:CONTROLLED TERM:

2022-23958
DRUGU
Worldwide management of hepatocellular carcinoma during
the COVID-19 pandemic.
Inchingolo R; Acquafredda F; Tedeschi M; Laera L;
Surico G; Surgo A; Fiorentino A; Spiliopoulos S;
de'Angelis N; Memeo R
Univ.Athens-Nat.+KapodistrianBari, Italy
World J.Gastroenterol. (2021), Volume 27, Number 25,
pp. 3780-3789, 42 refs., 1 Tab.
ISSN: 1007-9327
F Miulli Gen Reg Hosp, Dept Intervent Radiol Unit, Str
Prov 127 Acquaviva Santeramo, Bari, Italy, I-70021.
(Inchingolo R, e-mail: riccardoin@hotmail.it).
EnglishJournalWorldwide management of hepatocellular carcinoma during
coronavirus disease 2019 (COVID-19) pandemic isreviewed with reference to: surveillance;interventional radiology; surgery; oncology; andradiotherapy. Drugs discussed are lenvatinib, sorafenib
and bevacizumab. Results suggest that COVID-19
pandemic has strongly impacted management of
oncological patient due to reduction of inpatient beds
and reallocation of nurses and doctors to COVID
departments that are rapidly developed in each hospital
to face pandemic. Despite this unexpected
reorganization of hospitals, necessity to continue tomanage patients with hepatocellular carcinoma has
required continuation of multidisciplinary management
while reducing risk of COVID-19 negatively affecting
short and long-term oncological outcome.
T THERAPEUTICS; B BIOCHEMISTRY
14 Enzyme Inhibitors; 51 Chemotherapy-clinical; 69
Reviews
ADVANCED *TR; LIVER *TR; HEPATOPATHY *TR; HEPATOMA*TR; NEOPLASM *TR; IN-VIVO *FT; CASES *FT; REVIEW*FT; CYTOSTATIC *FT; DRUG-COMPARISON *FT; COMB.
*FT; ALONE *FT; ANGIOGENESIS *FT;ANGIOGENESIS-INHIBITOR *FT;PROTEIN-TYROSINE-KINASE-INHIBITOR *FT; VESSEL *FT[01] MAIN-TOPIC *FT; CYTOSTATICS *FT; TR *FT[02] LENVATINIB *TR; SORAFENIB *TR; BEVACIZUMAB *TR; TR*FTDISPLAY ALL of PRE-1983-RECORD
AN
1974-36436
DRUGU
TI
METAL IONS AND COMPLEXES IN ORGANIC REACTIONS. PART XVIII. STRUCTURALVARIATIONS IN THE PRODUCTION OF POLYCYCLIC HETEROCYCLIC SYSTEMS BY
IRON/II/-PROMOTED CYCLISATIONS OF NITRO-SUBSTITUTED PRECURSORS.
AUBACON R G R; HAMILTON S DLOBELFAST,U.K.
SO
J.CHEM.SOC. PERKIN TRANS.1 1974, NO.16, (1970), 5
DT
JournalSH
C CHEMISTRY
September 2023

8
DDFU/DRUGUCCIT

19 Heterocyclics
THIOPHENE COND.RING DIFF.THIENO 2,3-B - IMIDAZOLE IMIDAZO 1,2-A-QUINOXALINE AMIDINE ARYLAMINE 4-ANILINOBENZO G -PTERIDINE ACRIDINEARYLKETONE ACRID-9-ONE 3-NITRO-2-CF. -4- 4-PYRIDYLAMINO PYRIDINENITROARENE 1-O-NITROPHENYL-PYRAZOLE ETC. SYNTH.

DISPLAY MAX
AN
2022-23962
DRUGU
TI
Therapeutic Efficacy of Spironolactone for Central Serous
Chorioretinopathy.
AU
Han J Y; Kim Y J; Choi E Y; Lee J; Lee J H; Kim M; Byeon S H; Kim S S;
Lee C S
CS
Univ.Yonsei
LO
Seoul, South Korea
SO
Yonsei Med.J. (2022), Volume 63, Number 4, pp. 365-371, 32 refs., 2 Fig.
2 Tab.
ISSN: 0513-5796
AV
Yonsei Univ, Severance Hosp, 50-1 Yonsei Ro, Seoul, South Korea, 03722.
(Lee C S, e-mail: sklee219@yuhs.ac).
LA
EnglishDT
JournalAB
This interventional, open-label, retrospective study evaluated theoutcomes, recurrence rates and safety of p.o. spironolactone (Aldactone;
Pfizer) in management of central serous chorioretinopathy (CSC) in 103
patients. Central macular thickness and subretinal fluid height notably
decreased after spironolactone at all time points. Old age, history of
intravitreal bevacizumab injections and poor initial visual acuity werefactors associated with recurrence. Visual acuity notably improved inchronic CSC patients, but not at other evaluation periods in both acuteand chronic CSC patients. Subretinal fluid resolution (including partial
or complete resolution) was associated with complete- andpartial-responders or complete responders at last follow-up. In
conclusion, p.o. spironolactone results in anatomical improvements inboth acute and chronic CSC with excellent safety profiles.
ABEX
Methods
103 Patients (77 male, mean age 51.5 yr) with CSC received p.o.
spironolactone (50 mg/day b.i.d. for 3 mth).
Results
Mean duration of follow-up was 48.6 wk and mean duration of
spironolactone therapy was 15.5 wk. Central macular thickness decreased
from 395.4 uM at baseline to 320.9, 292.5, 275.3 and 249.9 uM at 1, 3
and 6 mth after treatment and last visit. Complete resolution ofsubretinal fluid was achieved in 13.1, 33.7, 52.5 and 81.2% of patients
at 1, 3, and 6 mth and last visit. In non-recurrence patients, central
macular thickness and subretinal fluid showed notable improvement after
spironolactone treatment at all timepoints. Subfoveal choroidal
thickness showed notable change at 3 and 6 mth and at the last visit. In
recurrence patients, central macular thickness and subretinal fluidheight showed notable improvement at all timepoints, similar to those in
non-recurrence patients, but unlike those in non-recurrence patients,
both best-corrected visual acuity and subfoveal choroidal thickness
showed no notable change after spironolactone at all timepoints inrecurrence patients. A notable decrease in subfoveal choroidal thickness
was observed at 3 mth in acute CSC patients, while it was observed at 1,
3, and 6 mth in chronic CSC patients. Percentage of eyes with complete
subretinal fluid resolution gradually increased in both acute andchronic CSC patients. 2/77 Male patients developed gynecomastia at 2 and3 mth after treatment. After discontinuation of drugs, their symptoms
resolved. One patient experienced mild elevation of serum creatinine 6
September 2023

9
DDFU/DRUGU

SH
CC
CT

mth after taking spironolactone, which returned to normal after
discontinuation of the medication. (L25)
T THERAPEUTICS; S ADVERSE EFFECTS
35 Adverse Reactions; 62 Ophthalmological[01] SPIRONOLACTONE *TR; SPIRONOLACTONE *AE; ALDACTONE *TR; ALDACTONE*AE; PFIZER *FT; SEROUS *TR; CHORIORETINOPATHY *TR; GYNECOMASTIA*AE; NEPHROPATHY *AE; ALOPECIA *AE; ACUTE *TR; CHRON. *TR;
MAMMA-DISEASE *AE; HAIR *AE; ALDOSTERONE-ANTAGONISTS *FT;ANGIOGENESIS-INHIBITORS *FT; DIURETICS *FT; IN-VIVO *FT; CASES *FT;P.O. *FT; RETROSPECTIVE *FT; OPHTHALMOLOGICAL-AGENT *FT;ALDOSTERONE-ANTAGONIST *FT; TR *FT; AE *FT; SPIRONOLA *RNDISPLAY BIB
AN
TI

AU
CS
LO
SO

AV
LA
DT
FA

2022-23953
DRUGU
Fibroblast growth factor receptor: A systematic review and meta-analysis
of prognostic value and therapeutic options in patients with urothelial
bladder carcinoma.
Parizi M K; Margulis V; Lotan Y; Mori K; Shariat S F
Univ.Tehran-Med.Sci.; Univ.Vienna-Med.; Univ.Karlova; Univ.Jordan;
Univ.Cornell; Univ.Texas-Syst.; Univ.Jikei-Med.; Univ.Sechenov
Vienna, Austria; Tehran, Iran
Urol.Oncol.-Semin.Orig.Investig. (2021), Volume 39, Number 7, pp.
409-421, 81 refs., 3 Fig. 3 Tab.
ISSN: 1078-1439
Med Univ Vienna, Comprehens Canc Ctr, Vienna, Austria. (Shariat S F,
e-mail: sfshariat@gmail.com).
EnglishJournal
AB; ABEX; AV; CC; CT; DDRN; JT; SH; TI

In North America
CAS Customer Center:
P.O. Box 3012
Columbus, Ohio 43210-0012
U.S.A.
800-753-4227 (North America)
614-447-3731 (worldwide)
E-mail: help@cas.org
Internet: www.cas.org

In Europe
CAS Customer Center EMEA
(represented by FIZ Karlsruhe)
P.O. Box 2465
76012 Karlsruhe
Germany

Phone:

Phone: +49-7247-808-555
E-mail: EMEAhelp@cas.org
Internet: www.stn-international.com

In Japan
JAICI (Japan Association forInternational Chemical Information)
Nakai Building
6-25-4 Honkomagome, Bunkyo-ku
Tokyo 113-0021
Japan
Phone:+81-3-5978-3601 (Technical Service)+81-3-5978-3621 (Customer Service)support@jaici.or.jp (Technical Service)customer@jaici.or.jp (Customer Service)
Internet: www.jaici.or.jp

E-mail:September 2023